May. 22 at 9:52 PM
$ABCL is still being priced like a traditional biotech company—at least until it is no longer treated that way.
This is not a prediction or a forecast. But if that moment ever arrives, there will likely be a wave of “experts” and “specialists” loudly arguing that it is overvalued and labeling it a meme stock, using conventional valuation models to justify where the price should be. My approach remains a 3–5 year horizon, and I will continue holding as long as the underlying thesis remains intact.
They might even be right in the short term, and the stock could pull back. That doesn’t change my perspective. I consider myself an owner, not a trader. Markets move through cycles of undervaluation and overvaluation, and I will stay focused on the long term.
